Keywords: بیوسیمیلارها; Biobased industry; Biosimilars; Food security; Industrial value chains; Public-private partnerships (PPPs);
مقالات ISI بیوسیمیلارها (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: بیوسیمیلارها; Granulocyte colony-stimulating factors (G-CSFs) filgrastim; Pegfilgrastim; Biosimilars;
Keywords: بیوسیمیلارها; Granulocyte colony stimulating factor; Biosimilars; Donor; Hematopoïetic stem cells; Side effects; G-CSF; Biosimilaires; Donneur volontaire; Cellules souches hématopoïétiques; Effets secondaires;
Keywords: بیوسیمیلارها; Biosimilars; Position statement; Recommendations; Interchangeability; Immunogenicity; Rheumatic diseases; Biosimilares; Posicionamiento; Recomendaciones; Intercambiabilidad; Inmunogenicidad; Enfermedades reumáticas;
Keywords: بیوسیمیلارها; Peptide mapping; Principal component analysis; Recombinant human growth hormone; On-column trypsin digestion; Biosimilars;
Keywords: بیوسیمیلارها; Rheumatoid arthritis; Spondyloarthritis; Psoriatic arthritis; Biosimilars; Switching; Disease-modifying antirheumatic drugs;
Keywords: بیوسیمیلارها; biosimilarity; biosimilars; monoclonal antibodies; oncology; switching;
Keywords: بیوسیمیلارها; Biologics; Biosimilars; Pharmacovigilance; Traceability; Adverse reactions; Legislation; Biológicos; Biosimilares; Farmacovigilancia; Trazabilidad; Acontecimientos adversos; Legislación;
Keywords: بیوسیمیلارها; Bioequivalence; Biosimilars; Follow-on; Generic; Innovator drug; Multiple sclerosis; Patients care; Proprietary medicine; Substandard copies; Toxicity;
Keywords: بیوسیمیلارها; Enoxaparin; Biosimilars; Preclinical; Wistar rats; Repeated toxicity studies;
Keywords: بیوسیمیلارها; biologics; biosimilars; comparability; manufacturing; regulatory guidance;
Keywords: بیوسیمیلارها; Biosimilars; Comparability exercise; Interchangeability; Challenges;
Keywords: بیوسیمیلارها; HER2-Positive breast cancer; Biosimilars; Anti-HER2 therapy; Trastuzumab;
Keywords: بیوسیمیلارها; Monoclonal antibodies (mAbs); Therapeutic antibodies; Biologicals; Biosimilars; Biobetters; Antibody engineering; Antibody drug conjugates (ADC); Bispecific antibodies; Manufacture; Degradation; Stability; Formulation;
Keywords: بیوسیمیلارها; Biological agents; Biosimilars; Drug information; Regulatory
Keywords: بیوسیمیلارها; biosimilars; pharmacovigilance; safety; arthritis; Inflammatory Bowl Disease (IBD); Nephrology;
Keywords: بیوسیمیلارها; Biopharmaceuticals; Biosimilars; N-glycosylation; Glycan separation; Glycan detection; Bioinformatics; Glycan analysis guidelines2-AA, anthranilic acid labeling; 2-AB, 2aminobenzamide labeling; ADCC, antibody-dependent cellular cytotoxicity; AEC, anion-ex
Keywords: بیوسیمیلارها; Economic evaluation; Health technology assessment; Trastuzumab; Metastatic breast cancer; Biosimilars;
Keywords: بیوسیمیلارها; Biosimilars; Autoimmune diseases; Rheumatoid arthritis; Ankylosing spondylitis; Psoriasis; Crohn's disease
Keywords: بیوسیمیلارها; Drug safety; Phenotypical variants; Personalized medicine; Psoriatic arthritis; Systemic disease; Biosimilars;
Keywords: بیوسیمیلارها; Biologicals; Biosimilars; Non-biological complex drugs; Glatiramoids; Liposomes; Nanomedicines; Iron-carbohydrate complexes;
Keywords: بیوسیمیلارها; Immunogenicity assessment; Biotherapeutic products; Biosimilars; Assays; Regulatory evaluation; WHO guidelines;
Keywords: بیوسیمیلارها; Posicionamiento; Sociedad Española de Reumatología; Biosimilares; RevisiónPosition paper; Spanish Society of Rheumatology; Biosimilars; Review
Keywords: بیوسیمیلارها; Biosimilars; Monoclonal Antibodies; Pharmacovigilance;
Keywords: بیوسیمیلارها; Anti-TNFα; Biosimilars; Crohn's disease; Inflammatory bowel disease; Ulcerative colitis
Keywords: بیوسیمیلارها; BPCI Act; Biologics Price Competition and Innovation Act; COFEPRIS; Comisión Federal para la Protección contra Riesgos Sanitarios; PAHO; Pan-American Health Organization; Biosimilars; Biopharmaceuticals; Regulatory framework; Comparability; Evaluation g
Keywords: بیوسیمیلارها; biologics; biosimilars; Crohn's disease; inflammatory bowel disease; steroid-sparing; ulcerative colitis
Keywords: بیوسیمیلارها; Anti-TNF-α; Antibody; Biosimilars; Inflammatory bowel diseases
Keywords: بیوسیمیلارها; Biologics; Biosimilars; Intended copies
Assessment of the higher order structure of Humira®, Remicade®, Avastin®, Rituxan®, Herceptin®, and Enbrel® by 2D-NMR fingerprinting
Keywords: بیوسیمیلارها; Monoclonal antibody therapeutics; NMR spectroscopy; Biosimilars;
Conocimiento sobre biosimilares en Atención Primaria: Un estudio de la Sociedad Española de Médicos de Atención Primaria (SEMERGEN)
Keywords: بیوسیمیلارها; Biosimilares; Conocimiento; Atención Primaria; España; Biosimilars; Knowledge; Primary Care; Spain;
Escenario actual de los medicamentos biocomparables en México: posicionamiento del Colegio Mexicano de ReumatologÃa, 2016
Keywords: بیوسیمیلارها; Biosimilares; Posicionamiento; Recomendaciones; Intercambiabilidad; Inmunogenicidad; Enfermedades reumáticas; Biosimilars; Position statement; Recommendations; Interchangeability; Immunogenicity; Rheumatic diseases;
Biosimilar switching and related medical liability
Keywords: بیوسیمیلارها; Biosimilars; Interchangeability; Substitution; Non-naïve patients; Informed consent; Medical liability;
A Randomized Phase I Study Comparing the Pharmacokinetics of HD201, a Trastuzumab Biosimilar, With European Union-sourced Herceptin
Keywords: بیوسیمیلارها; biosimilars; breast cancer; Herceptin; pharmacokinetics; trastuzumab;
Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI)
Keywords: بیوسیمیلارها; Biosimilars; Biologics; Extrapolation; Substitution; Interchangeability; Cost containment;
Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A retrospective multicenter study
Keywords: بیوسیمیلارها; Autologous hematopoietic cell transplantation; Stem cell mobilization; G-CSF; Biosimilars;
Fármacos biosimilares: un nuevo escenario en las terapias biológicas
Keywords: بیوسیمیلارها; Biológicos; Biosimilares; Farmacovigilancia; Trazabilidad; Acontecimientos adversos; Legislación; Biologics; Biosimilars; Pharmacovigilance; Traceability; Adverse reactions; Legislation;
Médicaments biosimilaires en oncologie
Keywords: بیوسیمیلارها; Biosimilaires; Oncologie; Biosimilars; Oncology;
Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists
Keywords: بیوسیمیلارها; biologicals; biosimilars; discrete choice experiment; preferences; ulcerative colitis;
Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34+ peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant
Keywords: بیوسیمیلارها; Allogeneic hematopoietic stem cell transplantation; Stem cell mobilization; G-CSF; Biosimilars
Physicians prefer greater detail in the biosimilar label (SmPC) - Results of a survey across seven European countries
Keywords: بیوسیمیلارها; Regulatory requirements; Biosimilars; Labelling survey; Physician preference; ASBM; Alliance for Safe Biologic Medicines; CHMP; Committee for Medicinal Products for Human Use; EMA; European Medicines Agency; EPAR; European Public Assessment Report; GaBI;
A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects
Keywords: بیوسیمیلارها; biosimilars; breast cancer; Herceptin®; pharmacokinetic equivalence; trastuzumab;
The challenging definition of naïve patient for biological drug use
Keywords: بیوسیمیلارها; Biologicals; Biosimilars; Secondary naïve patient; Drug biologic effect; Immunogenicity; Pure red cell aplasia;
Comment nous préparer à l'arrivée des biosimilaires de l'insuline ?
Keywords: بیوسیمیلارها; Insuline; analogues de l'insuline humaine; glargine; biosimilaires; Insulin; human insulin analogs; glargine; biosimilars;
N-glycosylation profile analysis of Trastuzumab biosimilar candidates by Normal Phase Liquid Chromatography and MALDI-TOF MS approaches
Keywords: بیوسیمیلارها; Monoclonal antibodies; Biosimilars; N-glycosylation; MALDI-TOF MS; Normal Phase Liquid Chromatography; 2AB fluorescent labeling, HILIC
Computational and functional analysis of biopharmaceutical drugs in zebrafish: Erythropoietin as a test model
Keywords: بیوسیمیلارها; hpf; hours post fertilization; dpf; days post fertilization; CHO; Chinese hamster ovary; EPO; erythropoietin; EPOR; erythropoietin receptor; rhEPO; recombinant human erythropoietin; hepo; human erythropoietin gene; hEPO; human erythropoietin protein; hEPO
Position Paper From the Spanish Society of Rheumatology on Biosimilar Drugs
Keywords: بیوسیمیلارها; Position paper; Spanish Society of Rheumatology; Biosimilars; ReviewPosicionamiento; Sociedad Española de Reumatología; Biosimilares; Revisión
Regional tenders on biosimilars in Italy: An empirical analysis of awarded prices
Keywords: بیوسیمیلارها; Italy; Tenders; Biosimilars; Competition;
Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: Innovators, biosimilars, and intended copies
Keywords: بیوسیمیلارها; Rheumatic diseases; Rheumatoid arthritis; Biopharmaceuticals; Tumor necrosis factor (TNF) antagonists; Biosimilars; Innovators
Putting the value into biosimilar decision making: The judgment value criteria
Keywords: بیوسیمیلارها; Biosimilars; Value in health; Immunogenicity; Decision process; Value chain